Key result
Apixaban was associated with a lower risk of stroke or systemic embolism compared with warfarin, rivaroxaban, and dabigatran among Medicare beneficiaries with NVAF.
Why the study?
The association between apixaban use and the risk of stroke/systemic embolism and major bleeding compared with other anticoagulants across demographic and socio-economic subgroups in NVAF patients was unclear.
Does apixaban reduce stroke/systemic embolism and major bleeding compared with other oral anticoagulants in adult Medicare beneficiaries with nonvalvular atrial fibrillation?
Cohort
Does apixaban reduce stroke/systemic embolism and major bleeding compared with other oral anticoagulants in adult Medicare beneficiaries with nonvalvular atrial fibrillation?
In a real-world Medicare cohort, apixaban was associated with lower risks of stroke/systemic embolism and major bleeding compared with warfarin, rivaroxaban, and dabigatran across demographic and socio-economic subgroups.
Answers are grounded in this paper and cite their sources.
May support apixaban preference in diverse Medicare NVAF subgroups; extends low-certainty evidence but leaves randomized confirmation open.
Objectives: To assess the association between apixaban use and the risk of stroke/systemic embolism (SE) and major bleeding (MB) compared with other anticoagulants (OACs) across demographic and socio-economic subgroups in the treatment of nonvalvular atrial fibrillation (NVAF). Methods: The study included adult NVAF patients initiating OAC treatment between 2013 and 2019 in the Medicare database. Inverse probability treatment weighted Cox proportional hazard models were used to assess stroke/SE and MB outcomes across various subgroups. Results: Overall, the adjusted risks of stroke/SE and MB were lower for apixaban compared with warfarin (stroke/SE: HR, 0.69, [95% confidence interval (CI): 0.65–0.74], MB: 0.59 [95% CI: 0.57–0.60]), rivaroxaban (stroke/SE: 0.88 [95% CI: 0.84–0.92], MB: 0.60 [95% CI: 0.58–0.61]) and dabigatran (stroke/SE: 0.88 [95% CI: 0.80–0.95], MB: 0.76 [95% CI: 0.72–0.80]). Among the low socio-economic status (SES) group, apixaban was associated with lower risk vs. warfarin (stroke/SE: 0.73 [95% CI: 0.69–0.77], MB: 0.60 [95% CI: 0.57–0.62]) and rivaroxaban (stroke/SE: 0.88 [95% CI: 0.83–0.94], MB: 0.61 [95% CI: 0.59–0.63]). Among medium SES patients, apixaban was associated with lower risk vs. warfarin (stroke/SE: 0.67 [95% CI: 0.63–0.71] MB: 0.60 [95% CI: 0.58–0.63]), rivaroxaban (stroke/SE: 0.85 [95% CI: 0.79–0.91], MB: 0.59 [95% CI: 0.56–0.61]) and dabigatran (stroke/SE: 0.85 [95% CI: 0.73–0.99], MB: 0.77 [95% CI: 0.70–0.84]). Apixaban was also associated with lower risks of stroke/SE and MB compared with other OACs among most other demographic, socio-economic subgroups. Conclusions: Apixaban was associated with lower risk of stroke/SE and MB than warfarin, rivaroxaban, dabigatran across most demographic, socio-economic subgroups.
No takes yet. Share an insight, caveat, or question.
Atreja et al. (2025) conducted a cohort in Nonvalvular atrial fibrillation (NVAF). Apixaban vs. Other anticoagulants (warfarin, rivaroxaban, dabigatran) was evaluated on Stroke/systemic embolism (SE) (HR 0.69, 95% CI 0.65-0.74). Apixaban was associated with a lower risk of stroke or systemic embolism compared with warfarin, rivaroxaban, and dabigatran among Medicare beneficiaries with NVAF.
Synapse has enriched 10 related papers. Consider them for comparative context: